远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

未开盘 06-10 16:09:07

5.100

+0.100

+2.00%

最高5.130	最低4.940	成交量530.85万
今开5.000	昨收5.000	日振幅3.80%
总市值181.05亿	流通市值181.03亿	总股本35.50亿
成交额2,665万	换手率0.15%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":5.1,"timestamp":1781078947002,"preClose":5,"halted":0,"volume":5308500,"delay":0,"changeRate":0.019999999999999928,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"未开盘","change":0.1,"latestTime":"06-10 16:09:07","open":5,"high":5.13,"low":4.94,"amount":26646519,"amplitude":0.038,"askPrice":5.11,"askSize":2500,"bidPrice":5.1,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.3544,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":0,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":5,"dividendRate":0.05098,"openAndCloseTimeList":[[1781055000000,1781064000000],[1781067600000,1781078400000]],"volumeRatio":1.193324,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512/","defaultTab":"news","newsList":[{"id":"1197835522","title":"远大医药与华东医药等达成协议 将供应药品制剂及原料等","url":"https://stock-news.laohu8.com/highlight/detail?id=1197835522","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197835522?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:07","pubTimestamp":1780909621,"startTime":"0","endTime":"0","summary":"根据一项新达成的协议，远大医药（中国）有限公司将向华东医药股份有限公司及其他相关方供应药品制剂、原料药及其他相关产品。\n此项合作旨在整合双方在医药领域的资源与优势，通过稳定的供应链安排，保障相关药品及原料的及时供应。协议的履行预计将对双方的业务发展产生积极影响。\n远大医药作为供应方，其产品线覆盖范围及生产能力是此项合作的基础。而华东医药等作为接收方，其市场渠道与分销网络将有助于相关产品的后续推广与销售。此次合作展现了医药企业间强化产业协同、优化资源配置的市场趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641175999","title":"远大医药(00512)核药合作伙伴重磅产品亮相ASCO 全球首创RDC药物硬核数据夯实全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2641175999","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641175999?lang=zh_cn&edition=full","pubTime":"2026-06-07 18:09","pubTimestamp":1780826974,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药核药领域的重要战略合作伙伴Telix Pharmaceuticals Limited 全球创新产品TLX591-Tx重磅亮相2026 ASCO年会，其治疗转移性去势抵抗性前列腺癌的全球III期临床试验的第一部分试验数据完成首次大会口头汇报，展现了该产品优异的临床安全性以及药代动力学特征，充分验证了该产品的临床潜力，未来或将为mCRPC精准治疗再添全新利器。WHO国际癌症研究机构发布的最新数据显示，2022年全球前列腺癌新发病例146.8万，死亡人数近40万。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RDC","BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045583","title":"远大医药5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045583","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126045583?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:41","pubTimestamp":1780483317,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年6月3日发布本公司截至2026年5月31日的股份变动月报表。报告显示，远大医药在此期间未进行新增发行、购回、注销或库藏股活动，股本保持稳定。根据公告，截至5月末，公司法定及注册股本维持为100,000,000,000股普通股，面值每股港币0.01元，相当于法定/注册股本总额港币10亿元。本次公告由公司秘书傅天忠签署。根据月报信息，截至5月31日，公司股本总数保持不变，未有股份发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637809470","title":"远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2637809470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637809470?lang=zh_cn&edition=full","pubTime":"2026-05-21 12:55","pubTimestamp":1779339306,"startTime":"0","endTime":"0","summary":"TLX101已获得美国FDA授予孤儿药资格认定，是全球范围内极具潜力的脑胶质瘤创新治疗方案。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法，临床开发进程持续领跑全球。未来若远大医药TLX101开发进展顺利，则有望提供全新的胶质母细胞瘤治疗手段，并为公司提供新的业绩增长点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635204903","title":"【券商聚焦】平安证券维持远大医药(00512)“推荐”评级 指其创新产品收入占比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2635204903","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635204903?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:40","pubTimestamp":1778661600,"startTime":"0","endTime":"0","summary":"金吾财讯 | 平安证券发布研报指，远大医药 2015年集采阶段性影响出清，公司创新和壁垒产品收入占比提升至50%左右，较上年提升近10个百分点。核药抗肿瘤及心脑血管介入产品收入12.82亿港元，同比增长约57.1%，其中核药抗肿瘤板块收入约9.49亿港元，同比增长61.0%，表现亮眼。公司自主研发的FAP靶点小分子RDC药物GPN01530获FDA批准开展用于实体瘤诊断的1/2期临床。维持\"推荐\"评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170596331","title":"远大医药4月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170596331","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170596331?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:49","pubTimestamp":1777884554,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年5月4日发布2026年4月股份变动月报，报告期为2026年4月1日至4月30日。公告显示，截至2026年4月30日，公司法定股本为100,000,000,000股普通股，面值每股港币0.01元，对应法定股本总额为港币1,000,000,000元。报告期内，已发行普通股股数合计为3,549,571,148股，与上月保持一致，库存股数量继续为0股，未发生新增发行、购回或注销等行为。公司同时确认，截至4月末，其公众持股量符合相关上市规则要求。本次月报由公司秘书傅天忠签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174844680","title":"远大医药（00512）2025年收入升至122.83亿元，核心业务稳步增长聚焦全球化与创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1174844680","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174844680?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:10","pubTimestamp":1777464657,"startTime":"0","endTime":"0","summary":"远大医药在最新年度报告中显示，2025年度实现收益122.83亿元，同比增长约5.48%。分业务来看，涵盖肿瘤、危重症、心脑血管、呼吸及五官科等多元化治疗领域的核心板块持续发力，创新药与仿制药研发同步推进，重点项目包括STC3141、FAP靶蛋白新型治疗方案、GPN01530、GPC-3及N2006等。从全年经营层面看，远大医药在专注提升运营效率的同时，通过多宗并购和资源整合，强化了呼吸、抗肿瘤及心脑血管等重点治疗领域的布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药（00512）2025年收入升至122.83亿元，核心业务稳步增长聚焦全球化与创新研发","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146031355","title":"远大医药拟回购不超过10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1146031355","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146031355?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:06","pubTimestamp":1777464409,"startTime":"0","endTime":"0","summary":"远大医药日前公告称，董事会已向股东提议，于即将召开的股东大会上申请授权回购最高不超过公司已发行股本总数10%的股份。根据公告，截至最后可行日期，远大医药已发行股份总数约为3,549,571,148股，若授权获批，最多可回购约354,957,114股。远大医药同时提醒股东，公司将于6月2日至5日暂停办理股份过户手续，股东大会定于6月5日上午在香港中环中心召开，将就回购授权相关提案进行表决。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药拟回购不超过10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046554","title":"董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046554","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629046554?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:56","pubTimestamp":1776855412,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，4月22日，董事会主席唐纬坤增持远大医药(00512)5万股，每股作价6.472港元，总金额为32.36万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260422/20260422185722_69561.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260422/20260422185722_69561.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","00512","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627982064","title":"远大医药：易甘泰在美国开展的治疗HCC临床研究达到了临床终点 完全缓解率90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627982064","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627982064?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:44","pubTimestamp":1776131040,"startTime":"0","endTime":"0","summary":"4月13日，远大医药（00512）发布公告，集团联营公司SirtexMedicalPtyLtd的SIR-Spheres钇[Y]微球注射液(\"易甘泰?\")在美国开展的用于治疗不可切除肝细胞癌(\"HCC\")临床研究(\"DOORwaY90研究\")成功达到了临床终点。该研究的结果显示，完全缓解率高达90%，最佳总体缓解率为99%，局部肿瘤控制率达100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704050982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","HCC","00512","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627455205","title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455205","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627455205?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:16","pubTimestamp":1776086193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，远大医药重磅核药SIR-Spheres钇[90Y]微球注射液(易甘泰)再度迎来里程碑进展！4月13日，远大医药发布公告称，公司钇[90Y]微球注射液在美国开展的用于治疗不可切除肝细胞癌临床研究已成功达到预设临床终点，取得了极为亮眼的临床数据。肝癌是全球第六大新发癌症以及第三大致死癌症。根据GLOBOCAN 2022年的数据，肝癌全球新发病例约87万，死亡病例约76万。此次钇[90Y]微球注射液成功达到海外临床","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912121","title":"远大医药：与香港大学达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912121","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912121?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:38","pubTimestamp":1775641120,"startTime":"0","endTime":"0","summary":"南财智讯4月8日电，远大医药（00512.HK）发布自愿公告，宣布与香港大学及其全资子公司港大科桥有限公司达成战略合作。双方将在学术研究、资源共享、人才培养及产品开发等方面深度合作，以创新抗菌药物开发为起点，由李学臣教授团队承接研发，旨在解决抗菌治疗领域未被满足的临床需求；后续香港大学将相关知识产权独家授权予远大医药，由其负责开发、注册及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698144219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190352339","title":"远大医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1190352339","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190352339?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:42","pubTimestamp":1775133729,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年4月2日披露3月股份变动月报表，报告期为2026年3月。根据公告披露，本月公司注册股本维持为100,000,000,000股，面值每股0.01港元，总额为1,000,000,000港元，未出现任何增加或减少。无新增股份发行、购回或注销，也未出现库藏股变动。公告同时显示，公司符合香港联交所对于公众持股量的相关要求。董事会确认本月并无涉及购回股份或其他可能影响已发行股本的事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624527327","title":"远大医药增资至34.3亿元 增幅约46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624527327","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624527327?lang=zh_cn&edition=full","pubTime":"2026-04-02 12:35","pubTimestamp":1775104517,"startTime":"0","endTime":"0","summary":"每经AI快讯，天眼查工商信息显示，近日，远大医药（中国）有限公司发生工商变更，注册资本由约23.5亿元人民币增至约34.3亿元人民币，增幅约46%。该公司成立于1990年2月，法定代表人为唐纬坤，经营范围包括药品生产、药品批发、药品进出口等。股东信息显示，该公司由远大医药（香港）有限公司、武汉和勤艾管理咨询有限公司等共同持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693176391.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693176391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0348827113.USD","06978","LU0634319403.HKD","BK1191","02096","LU1064131003.USD","09926","00512","BK1161","IE00B543WZ88.USD","LU0348784397.USD","159992","LU0348735423.USD","LU0417516902.SGD","LU2476274308.USD","LU2399975544.HKD","BK1588","LU1720050803.USD","LU2328871848.SGD","BK0239","LU1969619763.USD","LU0348767384.USD","LU0417516738.SGD","LU0417516571.SGD","LU1961090484.USD","LU2778985437.USD","09995","LU1064130708.USD","BK1587","LU1794554557.SGD","LU0348825331.USD","LU2488822045.USD","09969","BK1574","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348783233.USD","IE00B5MMRT66.SGD","688331","00013","LU2148510915.USD","BK1583","LU2476274720.SGD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145460499","title":"异动解读 | 董事会主席增持提振信心，远大医药盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145460499","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145460499?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:34","pubTimestamp":1774834494,"startTime":"0","endTime":"0","summary":"远大医药今日盘中大涨5.01%，引起了市场的广泛关注。消息面上，香港联交所最新资料显示，董事会主席唐纬坤于3月27日增持公司6万股，每股作价6.5港元，总金额为39万港元。增持后，其最新持股数目为106万股，持股比例为0.03%。此举被市场视为内部人士对公司未来发展充满信心的积极信号，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623699393","title":"远大医药获董事会主席唐纬坤增持6万股 每股作价6.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623699393","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623699393?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:11","pubTimestamp":1774829460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，3月27日，董事会主席唐纬坤增持远大医药（00512）6万股，每股作价6.5港元，总金额为39万港元。增持后最新持股数目为106万股，最新持股比例为0.03%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-30/doc-inhsthzk6668774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826365","title":"董事会主席唐纬坤增持远大医药(00512)6万股 每股作价6.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826365","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622826365?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:12","pubTimestamp":1774609945,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，3月27日，董事会主席唐纬坤增持远大医药(00512)6万股，每股作价6.5港元，总金额为39万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260327/20260327191250_33818.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260327/20260327191250_33818.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622182298","title":"核药领跑+创新突破：远大医药(00512)2025年价值兑现加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2622182298","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622182298?lang=zh_cn&edition=full","pubTime":"2026-03-27 08:50","pubTimestamp":1774572600,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，3月26日，远大医药公布了其2025年度业绩。其中，针对前列腺癌诊断的核药TLX591-CDx于2025年在国内顺利完成III期临床研究且达到研究终点，并于2026年初进入新药上市申请阶段，有望成为公司核药板块的下一个重磅商业化产品。创新产品持续突破，多元矩阵共筑护城河在技术优势向市场优势转化的逻辑驱动下，远大医药近年来实现了持续且可验证的成长。而STC3141这一First-in-Class药物的突破，则是远大医药创新研发的又一具象化体现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622862195","title":"远大医药(00512.HK)：2025年股东应占经调整经营性纯利为14.94亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622862195","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622862195?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:57","pubTimestamp":1774540621,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨远大医药公布2025年年度业绩，报告期内，收益约港币122.83亿元，同比增长约5.5%，如果撇除集采降价影响，收益同比上涨约14.8%。集团产品结构转型升级取得里程碑式成效，创新和壁垒产品收入占比实现历史性突破，首次提升至约50%，同比提升了近10个百分点，充分印证了集团战略布局的前瞻性，更为长期高品质发展构筑了坚实的核心支撑和强劲动能。董事会建议派发2025年年度末期股息每股港币0.169元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32102688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.1721},{"period":"3month","weight":-0.3023},{"period":"6month","weight":-0.3765},{"period":"1year","weight":-0.458},{"period":"ytd","weight":-0.3503}],"compareEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0604},{"period":"1year","weight":0.0101},{"period":"ytd","weight":-0.0477}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084101},{"month":2,"riseRate":0.709677,"avgChangeRate":0.105021},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015578},{"month":4,"riseRate":0.612903,"avgChangeRate":0.014044},{"month":5,"riseRate":0.451613,"avgChangeRate":0.07653},{"month":6,"riseRate":0.354839,"avgChangeRate":-0.047567},{"month":7,"riseRate":0.366667,"avgChangeRate":-0.015905},{"month":8,"riseRate":0.4,"avgChangeRate":0.007133},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.039275},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014834},{"month":11,"riseRate":0.5,"avgChangeRate":0.085694},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007596}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}